Publications by authors named "Olaya Hernandez-Frias"
Article Synopsis
- X-linked hypophosphatemia (XLH) is a condition that causes slow growth and bone problems, and regular treatments don't always help.
- Researchers found that using a type of treatment called MAPK inhibition, either alone or with growth hormone (GH), can help improve growth and bone structure in a special kind of mice used for this study.
- The best results came when MAPK inhibition was combined with GH, making it a hopeful new treatment for kids with XLH.
Objective: To find out if cardiovascular alterations are present in pediatric patients with X-linked hypophosphatemia (XLH).
Study Design: Multicentre prospective clinical study on pediatric patients included in the RenalTube database ( www.renaltube.
Article Synopsis
- Scientists studied mice with a condition called X-linked hypophosphatemia (XLH) to understand why they grow poorly and have bone problems.
- They found that these mice had issues with the growth plate in their bones, including problems with how cells grow and develop.
- The results showed that both the cartilage and bone structures were messed up, which might explain why these mice have growth issues and bone deformities.
BackgroundIn a model of growth retardation secondary to chronic kidney disease (CKD) induced by adenine, this study explores the effects of growth hormone (GH) therapy on growth plate and mineral metabolism.MethodsWeaning female rats receiving a 0.5% adenine diet during 21 days, untreated (AD) or treated with GH (ADGH) for 1 week, were compared with control rats receiving normal diet, either ad libitum or pair-fed with AD animals.
View Article and Find Full Text PDFPediatric chronic kidney disease (CKD) has peculiar features. In particular, growth impairment is a major clinical manifestation of CKD that debuts in pediatric age because it presents in a large proportion of infants and children with CKD and has a profound impact on the self-esteem and social integration of the stunted patients. Several factors associated with CKD may lead to growth retardation by interfering with the normal physiology of growth plate, the organ where longitudinal growth rate takes place.
View Article and Find Full Text PDFGrowth retardation is a major manifestation of chronic kidney disease (CKD) in pediatric patients. The involvement of the various pathogenic factors is difficult to evaluate in clinical studies. Here, we present an experimental model of adenine-induced CKD for the study of growth failure.
View Article and Find Full Text PDF